FlowCardia, Inc. Appoints Deborah DeFilippo CFO - Gilde Healthcare

FlowCardia, Inc. Appoints Deborah DeFilippo CFO

June 18, 2008

SUNNYVALE, Calif., June 18, 2008 — FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Deborah DeFilippo to the position of Chief Financial Officer. Ms. DeFilippo comes to FlowCardia with over 19 years of experience in Medical Devices. 

Most recently, Ms. DeFilippo served as Chief Financial Officer and Vice President, Business Development for the Guidant Cardiac Surgery business. Prior to that, she held a variety of executive positions at Guidant divisions as well as the Corporate Office of Guidant. Earlier, Ms. DeFilippo was the Director of Finance and Information Systems at Devices for Vascular Intervention prior to DVI’s acquisition by Guidant. Ms. DeFilippo holds a B.A. from Stanford University.

“We are tremendously pleased that Deborah will be joining FlowCardia. She is not only a very experienced financial executive but has also overseen such functions as Strategic Planning, Information Systems and Business Reengineering during her time with Guidant,”

said Wick Goodspeed, President and CEO of FlowCardia.

“Deborah will be a great addition to our management team and a substantial contributor to our sales growth and transition to profitability over the next few years.”

“I’m thrilled to be returning to the medical device field and joining FlowCardia at such an exciting time,”

said Ms. DeFilippo.

“FlowCardia is growing rapidly in its first year of commercialization and I am enthusiastic about the opportunity to help the Company become the leading CTO Device Company in the world.”

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture endovascular CTO recanalization systems. Additional information is available on the Company’s Web Site at www.flowcardia.com.

CONTACT
Mark Page
Sr. Director Marketing
FlowCardia, Inc.
T: 408-617-0352 ext. 301

SOURCE
FlowCardia, Inc.

Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta...
September 26, 2022

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022